OptimizeRx Corporation Common Stock OPRX

OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.

• Zacks Investment Research 23 sept

  Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars?

  The Trade Desk (TTD) is strengthening its healthcare advertising position through a new integration with OptimizeRx (OPRX), giving advertisers access to authenticated healthcare professional inventory across 400+ EHR systems reaching ~800,000 verified HCPs. The inventory will be available via TTD's OpenPath platform in Q4 2026. This partnership complements TTD's recent expansions with Veeva Crossix and IQVIA Digital, potentially attracting more pharma and life sciences advertisers. However, TTD shares have declined 71.9% over the past year and carry a Zacks Rank #4 (Sell) rating.

  

• GlobeNewswire Inc. 29 jul

  OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET

  OptimizeRx Corp. (Nasdaq: OPRX) announced it will hold a conference call on August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results ended June 30, 2026. The call will include management remarks followed by a Q&A session, with details and webcast access provided for investors.

  

• GlobeNewswire Inc. 23 jul

  OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

  OptimizeRx Corp. announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings over 20 years of pharmaceutical marketing experience from roles at Publicis Health Media and major life sciences companies including Lilly, Bayer, Johnson & Johnson, and AstraZeneca. She will lead OptimizeRx's marketing strategy and go-to-market initiatives as the company expands its point-of-care technology solutions.

  

• GlobeNewswire Inc. 25 jun

  OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

  OptimizeRx announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded in demand-side platforms and agency media planning platforms. The technology enables life sciences companies and marketers to build custom HCP audiences using natural-language prompts, combining real-world evidence with OptimizeRx's EHR network data. NLAB will be available for platform integration starting August 2026.